ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

insulin degludec

Also written as “insulin degludec/insulin aspart”, “insulin degludec/liraglutide” and “Insulin degludec”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 5 companies.

Drug pageInsulin degludec: every studyMany companies study it; this page follows only the 105 they lead. All 128 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 21, 2018105 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only1000 open or runningphase 4since Sep 21, 2018Jan 30, 2008none ahead
Tonghua Dongbao Pharmaceuticalits history only22 open or runningphase 3since Aug 14, 2024Jun 2, 2024none ahead
Gan & Lee Pharmaceuticals11 open or runningphase 1since Aug 18, 2025Aug 18, 2025none ahead
Sino Biopharmaceuticalits history only11 open or runningphase 3since Jul 5, 2021Jul 5, 2021none ahead
Sunshine Lake Pharmaits history only10 open or runningphase 3since Mar 6, 2023Mar 6, 2023none ahead

Also a collaborator on its studies: Profil Institut für Stoffwechselforschung.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gan & Lee Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 18, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07146347 · 14 planned · Germany

TargetBeta

INSR →read by rule
“Insulin receptor agonist”ChEMBL 37, by rule

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313
LY3938577Eli Lillyphase 23

Studies

The one study Gan & Lee Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07146347Diabetes Mellitus, Type 2 · Germany1RecruitingApr 1, 202614

How it is read

Names in the registry

  • “insulin degludec”, 73 entries
  • “insulin degludec/insulin aspart”, 35 entries
  • “insulin degludec/liraglutide”, 17 entries
  • “Insulin degludec”, 4 entries
  • “Insulin degludec/liraglutide”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.